SCHEMBL26124703

SCHEMBL26124703

CCOC(=O)CN1C2CCC1CN(c1ncc(C(F)(F)F)cn1)C2

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ SLC6A9 P48067 1/20 0.41
▸ ACACB O00763 1/20 0.41
▸ TRPV4 Q9HBA0 5/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ CHRM4 P08173 3/20 0.40
▸ KCNH2 Q12809 1/20 0.39
▸ GPR119 Q8TDV5 1/20 0.39
▸ PPARG P37231 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ POLB P06746 2/20 0.39
▸ PPARD Q03181 1/20 0.38
▸ PPARA Q07869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26125223 0.93 HPGD (0.42) HPGDSMN1; SMN2SLC6A9ACACBMEN1
SCHEMBL26125453 0.83 ACACB (0.42) SLC6A9ACACB
SCHEMBL30286308 0.82 ACACB (0.42) SLC6A9ACACBCHRM4KDM4E
SCHEMBL31647906 0.81 SMN1; SMN2 (0.46) HPGDSMN1; SMN2SLC6A9ACACBMEN1
SCHEMBL26128643 0.80 ACACB (0.43) HPGDSMN1; SMN2SLC6A9ACACBTRPV4
SCHEMBL26123468 0.77 GPR119 (0.48) HPGDSMN1; SMN2SLC6A9MEN1KMT2A
SCHEMBL30286395 0.76 ACACB (0.45) SLC6A9ACACBTRPV4CHRM4KCNH2
SCHEMBL26125507 0.76 TIPARP (0.43) SLC6A9ACACBCHRM4PPARGPPARD
SCHEMBL24962970 0.75 GPR119 (0.57) ACACBTRPV4KCNH2GPR119
SCHEMBL30286299 0.75 TIPARP (0.42) SLC6A9ACACBCHRM4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240336596-A1 PARP7 INHIBITOR AND USE THEREOF NOVOSTAR PHARMACEUTICALS, LTD. (CN) 2024-10-10 — — US disclosed
EP-4338737-A1 PARP7 INHIBITOR AND USE THEREOF Novostar Pharmaceuticals, Ltd. (CN) 2024-03-20 — — EP disclosed
WO-2023185073-A1 PARP7 INHIBITOR AND USE THEREOF 诺沃斯达药业(上海)有限公司 2023-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336596-A1 PARP7 INHIBITOR AND USE THEREOF PARP1, PARP3, PARP11 HPGD 335/4885SMN1; SMN2 1592/4885SLC6A9 2905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback